VitaNova Life Sciences Corporation VNOV
OTC PK
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -81.98% | 151.54% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -81.98% | 151.54% | |||
| Cost of Revenue | -80.85% | 286.52% | |||
| Gross Profit | -88.48% | -16.31% | |||
| SG&A Expenses | -59.23% | 38.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -76.58% | 185.83% | |||
| Operating Income | -11.19% | -335.33% | |||
| Income Before Tax | -14.21% | -329.12% | |||
| Income Tax Expenses | 100.72% | -236.66% | |||
| Earnings from Continuing Operations | -803.43% | 139.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -803.43% | 139.41% | |||
| EBIT | -11.19% | -335.33% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -804.76% | 139.62% | |||
| Normalized Basic EPS | -15.00% | -328.57% | |||
| EPS Diluted | -804.76% | 139.62% | |||
| Normalized Diluted EPS | -15.00% | -328.57% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||